Katharina Koepsel

Katharina Koepsel

Auto-generated profile, based on publicly available information

Katharina Koepsel

Department of Cardiology and Rhythmology, St. Josef Hospital, Ruhr University Bochum , Bochum

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
IEIbrahim El-Battrawy
Ibrahim El-Battrawy
KKKatharina Koepsel
Katharina Koepsel
DTDavid Tenbrink
David Tenbrink
BKBoldizsar Kovacs
Boldizsar Kovacs
TDTobias C. Dreher
Tobias C. Dreher
TBThomas Beiert
Thomas Beiert
Background: Data on the use of the wearable cardioverter‐defibrillator (WCD) among patients with myocarditis remain sparse. Consequently, evidence for guideline recommendations in this patient population is lacking. Methods and Results: In total, 1596 consecutive patients were included in a multicenter registry from 8 European centers, with 124 patients (8%) having received the WCD due to myocarditis and reduced left ventricular ejection fraction or prior ventricular tachyarrhythmia. The mean age was 51.6±16.3 years, with 74% being male. Patients were discharged after index hospitalization on heart failure medication: Angiotensin‐converting enzyme inhibitors (62.5%), angiotensin‐receptor‐neprilysin inhibitor (22.9%), aldosterone‐antagonists (51%), or beta blockers (91.4%). The initial median left ventricular ejection fraction was 30% (22%–45%) and increased to 48% (39%–55%) over long‐term follow‐up ( P <0.001). The median BNP (brain natriuretic peptide) level at baseline was 1702 pg/mL (565–3748) and decreased to 188 pg/mL (26–348) over long‐term follow‐up ( P =0.022). The mean wear time was 79.7±52.1 days and 21.0±4.9 hours per day. Arrhythmic event rates documented by the WCD were 9.7% for nonsustained ventricular tachycardia, 6.5% for sustained ventricular tachycardia, and 0% for ventricular fibrillation. Subsequently, 2.4% of patients experienced an appropriate WCD shock. The rate of inappropriate WCD shocks was 0.8%. All 3 patients with appropriate WCD shock had experienced ventricular tachycardia/ventricular fibrillation before WCD prescription, with only 1 patient showing a left ventricular ejection fraction <35%. Conclusions: Patients with myocarditis and risk for occurrence of ventricular tachyarrhythmia may benefit from WCD use. Prior ventricular arrhythmia might appear as a better risk predictor than a reduced left ventricular ejection fraction <35% in this population.

31 October 2025 in EP Europace
Verified
Journal Article
Open access
JRJohannes Rips
Johannes Rips
IEIbrahim El-Battrawy
Ibrahim El-Battrawy
MBMustafa Mousa Basha
Mustafa Mousa Basha
HLHendrik Lapp
Hendrik Lapp
AZAndreas Zietzer
Andreas Zietzer
TBThomas Beiert
Thomas Beiert